In the virus-inducible diabetes model, early discontinuation of ACT-777991 on Day 28 after infection showed a trend in improving the remission rate compared to aCD3 monotherapy, but to a lesser extent as compared to the chronic setting, suggesting the benefit of continuous blockade of the CXCR3 axis to revert diabetes. The gene discussed is CXCR3; the disease is infection.